论文部分内容阅读
目的探讨重组人生长激素(rhGH)对青春后期特发性矮小(ISS)女童的促生长效应。方法选取30例青春后期ISS女童。年龄12～14岁;身高143～149cm。分为治疗组和对照组,每组均为15例。治疗组患儿均单独接受GH治疗,治疗剂量为0.15IU.kg-1.d-1,临睡前皮下注射,疗程6个月;对照组未使用任何药物,观察6个月。结果治疗组生长速率(GV)由治疗前(2.20±0.56)cm.a-1提高至(3.40±1.37)cm.a-1,与对照组比较有统计学差异(P<0.05);骨龄(BA)由治疗前(13.3±1.7)岁增加到(13.9±1.6)岁,与对照组比较无统计学差异(P>0.05)。预测成年身高(PAH)由(146.2±3.1)cm提高到(149.3±3.4)cm,与对照组比较有统计学差异(P<0.05)。治疗组治疗前后GV和FAH比较差异均有统计学意义(Z=-2.05、-2.43,Pa<0.05);而BA比较差异无统计学意义(Z=0.65,P>0.05)。结论GH治疗能改善青春后期ISS女童的GV,而BA加速不明显,疗效肯定,无明显不良反应。
Objective To investigate the effects of recombinant human growth hormone (rhGH) on the growth-promoting effect of idiopathic shortness of life (ISS) in adolescent girls. Methods 30 young ISS girls were selected. Age 12 to 14 years old; height 143 ~ 149cm. Divided into treatment group and control group, each group was 15 cases. Children in the treatment group were treated with GH alone. The therapeutic dose was 0.15 IU.kg-1.d-1. Subcutaneous injection was given before going to sleep for 6 months. In the control group, no medication was used for 6 months. Results Compared with the control group, the GV increased from 2.20 ± 0.56 cm.a-1 to 3.40 ± 1.37 cm.a-1 in the treatment group (P <0.05) BA) increased from (13.3 ± 1.7) years before treatment to (13.9 ± 1.6) years old, showing no significant difference compared with the control group (P> 0.05). The predicted adult height (PAH) increased from (146.2 ± 3.1) cm to (149.3 ± 3.4) cm, which was significantly different from the control group (P <0.05). The difference of GV and FAH in the treatment group before and after treatment was statistically significant (Z = -2.05, -2.43, Pa <0.05), while there was no significant difference in BA (Z = 0.65, P> 0.05). Conclusions GH treatment can improve GV in adolescent ISS girls, while BA does not accelerate obviously. The curative effect is definite and there is no obvious adverse reaction.